MS stem-cell outcomes lack a uniform definition. Some series report 'stabilisation' in a majority and 'improvement' in a minority, but from unblinded, non-randomised cohorts, often against historical rather than true controls. Relapse-free periods of 1–2 years are reported; whether that reflects treatment or natural variation is unclear. Reviews find moderate-quality evidence for temporary immune suppression, not durable repair.
Ninety-two registered trials and 14 recruiting studies investigate stem-cell therapy in MS, across Europe, Asia and North America. Small series describe reduced relapse rates or stable disability scores; some show fewer inflammatory (gadolinium-enhancing) brain lesions over 6–12 months. MS is naturally variable, so separating stem-cell effects from disease fluctuation or concurrent disease-modifying drugs is difficult without controls. No trial has shown stem cells to be superior to established MS therapies; long-term data are sparse.
Sunt un candidat? → · Multiple Sclerosis: full overview → · Cost Scleroza Multiplă → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită